GeneMedix links with Malaysian firm for insulin production

- Last updated on GMT

GeneMedix and Penang Development of Malaysia have signed a letter
of intent that will see the two establish a new company in the
latter country's second city, at a cost of $34 million (€29m), for
the development, manufacture and commercialisation of human insulin

UK-based GeneMedix and Penang Development of Malaysia have signed a letter of intent that will see the two establish a new company in the latter country's second city, at a cost of $34 million (€29m), for the development, manufacture and commercialisation of human insulin.

Under the terms of the agreement, GeneMedix will out-license its existing insulin know-how to the newly created entity and will use its experience to construct and operate a current Good Manufacturing Practices-compliant facility in Penang. The total investment in the project will be funded from a variety of sources including development loans, grants and an issue of equity in the new firm to local investors.

GeneMedix will receive an up-front milestone payment and royalty fee payable on sales of bulk product. Meantime, the development of the full-scale industrial process for insulin will be completed by GeneMedix at its own expense and transferred into the facility, which is scheduled for completion in mid-2005.

Related products

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Follow us

Products

View more

Webinars